The estimated Net Worth of Seshadri Neervannan is at least $2.73 Million dollars as of 15 March 2024. Dr Neervannan owns over 13,245 units of Tarsus Pharmaceuticals stock worth over $2,214,743 and over the last 4 years he sold TARS stock worth over $23,895. In addition, he makes $486,665 as Chief Operating Officer at Tarsus Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr D TARS stock SEC Form 4 insiders trading
Dr has made over 4 trades of the Tarsus Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 13,245 units of TARS stock worth $421,191 on 15 March 2024.
The largest trade he's ever made was exercising 13,245 units of Tarsus Pharmaceuticals stock on 15 March 2024 worth over $421,191. On average, Dr trades about 2,528 units every 46 days since 2021. As of 15 March 2024 he still owns at least 69,646 units of Tarsus Pharmaceuticals stock.
You can see the complete history of Dr Neervannan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Seshadri Neervannan Ph.D. biography
Dr. Seshadri Neervannan Ph.D. is the Chief Operating Officer at Tarsus Pharmaceuticals.
What is the salary of Dr D?
As the Chief Operating Officer of Tarsus Pharmaceuticals, the total compensation of Dr D at Tarsus Pharmaceuticals is $486,665. There are 1 executives at Tarsus Pharmaceuticals getting paid more, with Dr. Bobak R. Azamian M.D. having the highest compensation of $663,304.
How old is Dr D?
Dr D is 53, he's been the Chief Operating Officer of Tarsus Pharmaceuticals since . There are 1 older and 5 younger executives at Tarsus Pharmaceuticals. The oldest executive at Tarsus Pharmaceuticals, Inc. is Michael Holdbrook, 68, who is the VP of Clinical Affairs.
What's Dr D's mailing address?
Seshadri's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.
Insiders trading at Tarsus Pharmaceuticals
Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita..., and William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
What does Tarsus Pharmaceuticals's logo look like?
Complete history of Dr Neervannan stock trades at Tarsus Pharmaceuticals
Tarsus Pharmaceuticals executives and stock owners
Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Bobak R. Azamian M.D.,
Co-Founder, Pres, CEO & Director -
Dr. Seshadri Neervannan Ph.D.,
Chief Operating Officer -
Leonard M. Greenstein,
Chief Financial Officer -
Kim Norman,
Sr. Director of Fin. -
Michael Holdbrook,
VP of Clinical Affairs -
Aziz Mottiwala,
Chief Commercial Officer -
Dianne C. Whitfield,
Chief HR Officer -
Matthew Rossen M.B.A.,
VP of Marketing -
Dr. Bryan Wahl J.D., M.D.,
Gen. Counsel -
David Nakasone,
Head of Investor Relations -
Jeffrey S Farrow,
See Remarks -
Scott W Morrison,
Director -
Michael Ackermann,
Director -
Jason E. Tester,
Director -
Capital Ix, Llc Vivo Capita...,
-
Life Sciences Ix, L.P.Fhmls...,
-
Limited Partnership Viii Ho...,
10% owner -
Jose M. Trevejo,
CHIEF MEDICAL OFFICER -
Bryan Wahl,
General Counsel -
Dianne C. Whitfield,
Chief Human Resources Officer -
Leonard M. Greenstein,
Chief Financial Officer -
Wendy L Yarno,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Mark J. Holdbrook,
V.P., Clinical Affairs -
Investments, Lpwong Roderic...,
-
Bhaskar Chaudhuri,
Director -
Andrew D. Goldberg,
Director -
Rosemary A Crane,
Director -
Elizabeth Yeu Lin,
Director -
Bobak R. Azamian,
President/CEO and Board Chair -
William J Phd Link,